gen1042
mAbexperimentalMulti-specific
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 17, 2019 (NCT04083599)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- CD40 ligandINHIBITOR
CD40LG inhibitor
TNFRSF9 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06057038 | Phase 1 | Oct 31, 2023 | Biontech, Genmab |
| NCT05491317 | Phase 1/Phase 2 (Phase 2) | Jan 31, 2023 | Biontech, Genmab |
| NCT04083599 | Phase 1/Phase 2 (Phase 2) | Sep 17, 2019 | Biontech, Genmab |
Showing 3 of 3 trials
Page 1 / 1